2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice
This CME-accredited activity 2023 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Platinum Sponsor: Bristol Myers Squibb
Gold Sponsors: Genentech, Janssen Biotech
Bronze Sponsor: Novartis
- Cancer care professionals
- Practicing medical oncologists/hematologists
- Radiation oncologists
- Medical oncology and hematology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
A limited number of guestrooms have been reserved at the Gaylord Opryland Hotel for participants of this meeting at the discounted nightly single/double rate of $319/night. Reservations by attendees must be made on or before 5 PM CST on Friday, August 8, 2023, to receive the discounted room rate. Individual Reservations for the Event will be made by individual attendees directly with Marriott reservations at (877) 351-5021.
Upon successful completion of this educational activity, participants will be able to:
- Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
- Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
- Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors
- Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies
Conference chairs: Nitin Jain, MD, Navneet Majhail, MD, MS, Shaji Kumar, MD, & Sonali Smith, MD
All times below are in Central Daylight Time (CDT)
Day 1 - September 15, 2023
Conference Space: General session is in Cheekwood ABC and exhibit hall is in Magnolia Ballroom.
12:00 PM - 01:00 PM: REGISTRATION, EXHIBITS, & SOCIALIZE
01:00 PM - 01:15 PM: OPENING REMARKS - Navneet Majhail, MD, MS
01:15 PM- 01:30 PM: Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA
01:30 PM - 03:00 PM: SESSION 1: ALL
Chairs: Lori Muffly, MD, MS & Nitin Jain, MD
01:30 PM - 01:45 PM: How do I incorporate CAR T in my clinical practice?- Lori Muffly, MD, MS
01:45 PM - 02:00 PM: Anything new in T-ALL therapy? - Nitin Jain, MD
02:00 PM -03:00 PM: Q & A and Case-Based Panel Discussion- Minoo Battiwalla MD, MS, Lori Muffly, MD, MS & Nitin Jain, MD
03:00 PM – 03:30 PM: BREAKS & EXHIBITS
03:30 PM – 05:00 PM: SESSION 2: AGGRESSIVE LYMPHOMAS
Chairs: Nirav Shah, MD & Sairah Ahmed, MD
03:30 PM - 03:45 PM: Sequencing of CAR-T- Olalekan O. Oluwole, M.B.B.S., M.D.
03:45 PM - 04:00 PM: Focus on elderly patients and CAR-T- Sairah Ahmed, MD
04:00 PM - 05:00 PM: Q & A and Case-Based Discussion Nirav Shah, MD & Sairah Ahmed, MD, Olalekan O. Oluwole, M.B.B.S., M.D., Bhagirathbhai Dholaria, M.D.
05:00 PM - 06:00 PM: ABSTRACT SESSION
Session Chair: Naveen Pemmaraju, MD
05:00 PM- 05:12 PM: Evaluation of Emergent FLT3 Mutations at Relapse in Patients with Wild-type FLT3 Acute Myeloid Leukemia- Fadi Haddad, MD
05:12 PM - 05:24 PM: A CD5 gene signature identifies diffuse large B-cell lymphomas sensitive to Brutonʼs tyrosine kinase inhibition- Alan Cooper
05:24 PM- 05:36 PM: Prognostic risk signature in patients with newly diagnosed acute myeloid leukemia treated with hypomethylating agents and venetoclax- Alex Bataller, MD, PhD
05:36 PM- 05:48 PM: Assessment of Central Nervous System Responses in Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Receiving Brexucabtagene Autoleucel as an FDA-Approved Standard of Care- Gregory Roloff, MD
05:48 PM- 06:00 PM: Durable Responses in Acute Lymphoblastic Leukemia Using Targeted Therapies Approved for Acute Myeloid Leukemia- Rafael Madero Marroquin, MD
Day 2 - September 16
07:00 AM - 08:00 AM: REGISTRATION, EXHIBITS, & SOCALIZE
08:15 AM – 09:45 AM: SESSION 3: MULTIPLE MYELOMA – NEWLY Dx
Chairs: Muzaffar H. Qazilbash, MD & Noopur Raje, MD
08:15 AM - 08:30 AM: Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Noopur Raje, MD
08:30 AM - 08:45 AM: Transplant for MM – does it still have a role? - Muzaffar H. Qazilbash, MD
08:45 AM - 09:00 AM: Maintenance approaches for MM – one drug or two? - Shaji Kumar, MD
09:00 AM - 09:45 AM: Q & A and Case- Based Discussion- Shuang Fu, MD, PhD, Muzaffar H. Qazilbash, MD, Noopur Raje, MD, Shaji Kumar, MD
09:45 AM – 10:30 AM: BREAKS & EXHIBITS
Product Theater Sponsored by Janssen PT
Title: A Treatment for Adult Patients with RRMM who have Received at Least Four prior lines of therapy, including a proteasome inhibitor, an
immunomodulatory agent and an anti-CD38 monoclonal antibody.
Speaker name: Rafat Abonour, MD
10:30 AM – 12:00 PM: SESSION 4: AML/MDS
Chairs: Stephen Strickland, MD, MSCI, Alexander Perl, MD
10:30 AM - 10:45 AM: Frontline Therapy of AML in 2023 - Tapan Kadia, MD
10:45 AM - 11:00 AM: Updates in treatment of MDS - Hetty Carraway, MD
11:00 AM - 11:20 AM: ICC vs. WHO: Clash of the Titans- Sanam Loghavi, MD
11:20 AM - 12:00 PM: Q & A and Case- Based Discussion- Somedeb Ball, MD, Jonathan A. Abbas, MD, Stephen Strickland, MD, MSCI, Alexander Perl, MD, Sanam Loghavi, MD, Hetty Carraway, MD, and Tapan Kadia, MD
12:00 PM - 01:00 PM: LUNCH, EXHIBITS & INDUSTRY SPONSORED SYMPOSIA
12:00 – 12:45 PM- Product Theater Sponsored by BMS- in Cheekwood F
Title: Treatment Options in Relapsed Refractory Multiple Myeloma: Clinical Data and Patient Cases
A presentation on Relapsed Refractory Multiple Myeloma including disease state overview, clinical trials, and hypothetical patient cases with questions.
Speaker: Kelly McCaul, MD. University of Tennessee Cancer Specialists, Knoxville, TN
01:00 PM - 01:30 PM: (KEYNOTE) TREATMENT OF HODGKIN LYMPHOMA IN 2023 - Ranjana H. Advani, MD
01:30 PM - 03:00 PM: SESSION 5: CLL
Chairs: Nitin Jain, MD & Jacqueline Barrientos, MD, MS
01:30 PM - 01:45 PM: BTK or BCL2i or Both for Frontline CLL- Mazyar Shadman, MD, MPH
01:45 PM - 02:00 PM: Pirtobrutinib, CAR T, and others. How to incorporate it in practice?- William Wierda, MD, PhD
02:00 pm - 02:20 PM: Richter transformation. What’s new?- Sameer A Parikh, MBBS
02:20 PM - 03:00 PM: Q & A and Case- Based Discussion Nitin Jain, MD, Jacqueline Barrientos, MD, MS, Mazyar Shadman, MD, MPH, William Wierda, MD, PhD, Sameer A Parikh, MBBS, Shilpan Shah, MD
03:00 PM – 03:30 PM: BREAKS & EXHIBITS
03:30 PM – 05:00 PM: SESSION 6: LOW-GRADE LYMPHOMAS
Chairs: Sonali Smith, MD & Brian T. Hill, MD, PhD
03:30 PM - 03:45 PM: Are bi-specifics really going to have a role in indolent lymphomas?- Brian T. Hill, MD, PhD
03:45 PM - 04:00 PM: Sequencing of treatments in 2L+ settings- Loretta Nastoupil, MD
04:00 PM - 05:00 PM: Q & A and Case- Based Panel Discussion Sonali Smith, MD, Brian T. Hill, MD, PhD, and Loretta Nastoupil, MD
05:00 PM - 6:00 PM: Raise a Toast for Women in Hematology
**This is a non-CME activity**
Sponsored by Jazz Pharmaceuticals
- 05:00 PM- 05:15 PM: Career Reflection: Sonali Smith, MD
- 05:15 PM- 05:30 PM: Career Reflection: Ishwaria Subbiah, MD, MS
- 05:30 PM- 06:00 PM: Panel Discussion: Loretta Nastoupil, MD, Sanam Loghavi, MD
Day 3 - September 17
07:00 AM - 08:00 AM: REGISTRATION, EXHIBITS, & SOCIALIZE
08:15 AM- 08:45 AM: Precision Medicine in Oncology- Vivek Subbiah, MD
08:45 am - 10:10 AM: SESSION 7: CML/MPN
Chairs: Gabriela Hobbs, MD & Naveen Pemmaraju, MD
08:45 AM - 09:00 AM: Incorporating novel JAKi and other therapies in MF management- Ashwin Kishtagari, MD
09:00 AM - 09:15 AM: Unanswered questions in CML in 2023- Jorge Cortes, MD
09:15 AM - 09:30 AM: Advanced MPN. Unanswered questions- Anand Patel, MD
09:30 AM -10:10 AM: Q & A and Case- Based Discussion- Srinivas Tantravahi, MD, Gabriela Hobbs, MD, Naveen Pemmaraju, MD, Ashwin Kishtagari, MD, Jorge Cortes, MD, Anand Patel, MD, Kamran M. Mirza, MD PhD
10:10 AM - 10:30 AM: BREAKS & EXHIBITS
10:30 AM - 12:00 PM: SESSION 8: MULTIPLE MYELOMA – R/R
Chairs: Shaji Kumar, MD & Natalie Callander, MD
10:30 AM - 10:45 AM: Management of early relapses in myeloma-choosing the right combination - Natalie Callander, MD
10:45 am - 11:00 AM: Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics - Jesus Berdeja, MD
11:00 AM - 11:15 AM: Non-immune approaches for advanced myeloma - Ajay Nooka, MD, MPH, FACP
11:15 AM - 12:00 PM: Q & A and Case- Based Discussion Shaji Kumar, MD, Natalie Callander, MD, Jesus Berdeja, MD, and Ajay Nooka, MD, MPH, FACP
12:15 PM: ADJOURN
The conference will be held in the Magnolia area of the hotel. The exhibitor space is in the Magnolia Ballroom and the general session is in Cheekwood ABC.
Guest room reservation
A limited number of guest rooms have been reserved at the Gaylord Opryland Hotel for participants of this meeting at the discounted nightly single/double rate of $319/night.
Reservations must be made on or before 5 PM CST on Friday, August 8, 2023, to receive the discounted room rate.
Applicable taxes will be added to room rates (currently 9.25% State Tax, 6% Occupancy Tax and $2.50 City Tax). Rates quoted are for single/double occupancy. Each additional person to a room is $20.00.
Children twelve (12) years and under are free when occupying the same room as their parents. Atrium view upgrades are an additional $60.00.
Reservations must be made directly with Marriott reservations at (877) 351-5021 or follow the link below to receive the discounted rate.
Room reservation Link -
RESORT FEE: The prevailing resort fee, currently $25.00 plus applicable taxes, will be added to the guest room rate. This fee will cover several in-room amenities which at the time of check-in will include:
Resort Wide Internet Access to include: Enhanced in-room wireless Internet Access for up to six (6) devices and Basic Wireless Internet Access in Public Areas and Convention Center on a Shared Network
Unlimited local and long-distance calls
Daily shuttle service to Opry Mills and The Inn at Opryland
Shuttle transportation to scheduled Grand Ole Opry and General Jackson Showboat performances
Bottled water (2 daily) replenished once daily with housekeeping service
Daily credit of up to $10 per room toward dry cleaning (credit is not cumulative through stay)
Transportation to Gaylord Springs Golf Links, practice range access and daily bucket of balls (rental club provided; appropriate attire required)
The parking fee is currently $33.00 plus tax for self-parking and $45.00 plus tax for valet parking. The hotel will provide $10 off the currently prevailing parking rate to the attendees of the conference. Attendees are responsible for covering the costs of parking themselves.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTEREST:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Commercial Support Acknowledgment
This activity is supported by independent medical education grants from the following companies:
- ADC Therapeutics
- Novartis Pharmaceuticals Corporation.
- 13.75 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 13.75 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 13.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 13.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 13.75 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 13.75 Contact Hours.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
- No refunds will be issued if registration is cancelled after that date.
No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.